Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAD | P27708 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 6/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439697 | 1.00 | CAD (0.47) | CADCYP2D6LMNABLMTSHR | |
| SCHEMBL29953785 | 1.00 | CAD (0.47) | CADCYP2D6LMNABLMTSHR | |
| SCHEMBL5852589 | 0.88 | CAD (0.41) | CADCYP2D6LMNABLMTSHR | |
| SCHEMBL4459100 | 0.83 | CAD (0.39) | CADCYP2D6LMNABLMTSHR | |
| SCHEMBL10077812 | 0.81 | CAD (0.34) | CAD | |
| SCHEMBL873651 | 0.77 | — | — | |
| SCHEMBL6603156 | 0.77 | — | — | |
| SCHEMBL6602740 | 0.77 | — | — | |
| SCHEMBL15057980 | 0.77 | CYP2D6 (0.36) | CADCYP2D6LMNABLMTSHR | |
| Lithium SCHEMBL29627538 | 0.76 | CAD (0.44) | CADCYP2D6LMNABLMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6060586-A | Ureins derived from alpha, omega-diamono acids and process for their preparation | SOLVAY (SOCIETE ANONYME) (BE) | 2000-05-09 | — | — | US | claimed |
| EP-0629612-B1 | Process for the preparation of ureas derived from alpha, omega-diaminoacids | SOLVAY (BE) | 1999-12-01 | — | — | EP | claimed |
| EP-0260057-A2 | 2-Oxo-4-carboxy-pyrimidines | THE UNIVERSITY OF MELBOURNE (AU) | 1988-03-16 | — | — | EP | claimed |
| US-7705008-B2 | Prostaglandin analogs | ALLERGAN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090069309-A1 | PROSTAGLANDIN ANALOGS | ALLERGAN, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-7427614-B2 | Prostaglandin analogs | ALLERGAN, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20060276461-A1 | Prostaglandin analogs | ALLERGAN, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7030214-B2 | Ureins derived from α, ω, diamino acids and process for their preparation | SOLVAY (SOCIETE ANONYME) (BE) | 2006-04-18 | — | — | US | disclosed |
| US-6727366-B2 | SUCH AS (4S)-N(((1R)-1-((3AS),4S,6S,7AR)-HEXAHYDRO-3A,5,5-TRIMETHYL-4,6-METHANO1 -1,3,2-BENZODIOXABOROL-2-YL)PROPYL)-3,5-(((2S)-3-METHYL-2-((PHENYLACETYL -AMINO)-BUTANOYL)-2-OXO-1-(3-P HENYLPROPYL)-4-IMIDAZOLIDINECARBOXAMIDE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-27 | — | — | US | disclosed |
| US-20030100768-A1 | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-05-29 | — | — | US | disclosed |
| WO-2002048157-A2 | IMIDAZOLIDINONES AND THEIR RELATED DERIVATIVES AS HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-20020058784-A1 | Ureins derived from alpha, omega, -diamond acids and process for their preparation | CALLENS ROLAND (BE) | 2002-05-16 | — | — | US | disclosed |
| US-6310178-B1 | AS THE N-TERMINAL RESIDUE OF BIOLOGICALLY ACTIVE PEPTIDES, E.G, THYROTROPIN RELEASING HORMONE (BY REPLACING THE N-TERMINAL PYROGLUTAMYL GROUP); IMPARTING INCREASED RESISTANCE TO PROTEOLYTIC DIGESTION | SOLVAY, S.A. (BE) | 2001-10-30 | — | — | US | disclosed |
| US-6060586-A | Ureins derived from alpha, omega-diamono acids and process for their preparation | SOLVAY (SOCIETE ANONYME) (BE) | 2000-05-09 | — | — | US | disclosed |
| EP-0629612-B1 | Process for the preparation of ureas derived from alpha, omega-diaminoacids | SOLVAY (BE) | 1999-12-01 | — | — | EP | disclosed |
| EP-0922696-A2 | Urea derivatives of alpha, omega-diaminoacids and peptides | SOLVAY (Société Anonyme) (BE) | 1999-06-16 | — | — | EP | disclosed |
| EP-0922696-A2 | Urea derivatives of alpha, omega-diaminoacids and peptides | SOLVAY (Société Anonyme) (BE) | 1999-06-16 | — | — | EP | disclosed |
| EP-0629612-A1 | Ureas derived from alpha, omega-diaminoacids and process for their preparation | SOLVAY (Société Anonyme) (BE) | 1994-12-21 | — | — | EP | disclosed |
| EP-0260057-A2 | 2-Oxo-4-carboxy-pyrimidines | THE UNIVERSITY OF MELBOURNE (AU) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100768-A1 | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors | PRSS1, SPINT2, SERPINB1 | CAD 3294/4885CYP2D6 654/4885LMNA 2518/4885 |
| US-20020058784-A1 | Ureins derived from alpha, omega, -diamond acids and process for their preparation | UPP1, URB2, UFM1 | CAD 926/4885CYP2D6 3471/4885LMNA 37/4885 |
| US-20090069309-A1 | PROSTAGLANDIN ANALOGS | PTGES, PTGIS, PTGER1 | CAD 4214/4885CYP2D6 382/4885LMNA 1499/4885 |
| US-20060276461-A1 | Prostaglandin analogs | PTGES, PTGIS, PTGER1 | CAD 4214/4885CYP2D6 382/4885LMNA 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.